ALT - Altimmune, Inc.
4.50 +0.03 (0.67%)
After hours: 7:59PM EDT
| Previous Close | 4.65 |
| Open | 4.57 |
| Bid | 4.36 x 900 |
| Ask | 4.55 x 1000 |
| Day's Range | 4.05 - 4.69 |
| 52 Week Range | 3.55 - 85.20 |
| Volume | 1,235,632 |
| Avg. Volume | 807,740 |
| Market Cap | 30.786M |
| Beta (3Y Monthly) | 1.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -86.80 |
| Earnings Date | Aug 8, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2017-01-20 |
| 1y Target Est | 10.00 |
- ACCESSWIRE•15 hours ago
Today’s Research Reports on Stocks to Watch: Altimmune and MannKind
NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Altimmune and MannKind were two biotech stocks flying higher in Tuesday’s session. Altimmune didn’t have any particular news but MannKind announced along ...
- InvestorPlace•9 days ago
Why Altimmune Stock Is Sliding Lower Today
According to Altimmune (NASDAQ:ALT), the company has entered into a purchase agreement with a several institutional investors. The common units include one common share of Altimmune stock, as well as a warrant to purchase an additional share for the same price. It also includes a warrant to purchase an additional share of ALT stock for a price of $5.39.
- GlobeNewswire•10 days ago
Altimmune Announces $25 million Registered Direct Offering
Each common unit is being sold at a public offering price of $5.40 and consists of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $5.40. Each pre-funded unit is being sold at a public offering price of $5.39 and consists of a pre-funded warrant to purchase one share of common stock at an exercise price of $0.01 per share and a warrant to purchase one share of common stock at an exercise price of $5.40. The public offering price of each pre-funded unit is equal to the public offering price of each common unit being sold to the public in this offering, minus $0.01.
- GlobeNewswire•15 days ago
Altimmune Closes on $16.9 Million in Funding
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced it closed the previously announced underwritten public offering of common units and pre-funded units for gross proceeds of $12 million. Together with the Company’s registered direct offering announced on September 24, the Company received aggregate gross proceeds of $16.9 million. Altimmune intends to use the net proceeds of approximately $14.4 million from these offerings for the continued advancement of development activities for the Company’s clinical-stage product pipeline, general corporate purposes, strategic growth opportunities and repayment of the Company’s outstanding $1.5 million in aggregate principal amount of convertible notes.
- ACCESSWIRE•17 days ago
Today’s Research Reports on Stocks to Watch: Aytu Bioscience and Altimmune
NEW YORK, NY / ACCESSWIRE / October 1, 2018 / Shares of Altimmune were collapsing in Friday’s session as the company announced the pricing of an underwritten public offering. Shares of Aytu Biosciences were seeing gains of over 13% despite any significant news. Aytu BioScience, Inc. shares were up 13.11% on Friday on nearly 2.8 million shares traded.
- GlobeNewswire•20 days ago
Altimmune Announces Pricing of $12 Million Underwritten Public Offering
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the pricing of an underwritten public offering of common units and pre-funded units for a combined total of 2,400,000 units. Each common unit is being sold at a public offering price of $5.00 and consists of a share of its common stock and a warrant to purchase one share of common stock at an exercise price of $6.00. Each warrant will be exercisable immediately and will expire five years from the date of issuance. Each pre-funded unit consists of a pre-funded warrant to purchase one share of our common stock at an exercise price of $0.01 per share and a warrant.
- GlobeNewswire•24 days ago
Altimmune Announces $4.9 million Registered Direct Offering of Common Stock
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced it has entered into purchase agreements with several institutional investors for the purchase in a registered direct offering of 286,633 shares of its common stock at a public offering price of $17.02 per share, for expected gross proceeds of approximately $4.9 million before placement agent fees and other offering expenses payable by Altimmune. The securities described above are being offered by Altimmune pursuant to a registration statement on Form S-3 (File No. 333-217034) that was declared effective by the Securities and Exchange Commission (SEC) on April 6, 2017. A final prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, by contacting Roth Capital Partners, LLC, Attention: Equity Capital Markets, 888 San Clemente Drive, Suite 400, Newport Beach, California 92660, by telephone at (800) 678-9147 or e-mail at rothecm@roth.com.
- GlobeNewswire•24 days ago
Altimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield™ Development
New funding will allow examination of mucosal immune response and additional vaccine characterization. GAITHERSBURG, Md., Sept. 24, 2018-- Altimmune, Inc., a clinical-stage immunotherapeutics company, ...
- ACCESSWIRE•28 days ago
Today’s Research Reports on Stocks to Watch: Molecular Templates and Altimmune
Shares of Molecular Templates were also exploding on the news that the company had entered into an agreement with Japan's Takeda Pharmaceutical Co Ltd for jointly developing CD38-targeted ETNs for treating patients with diseases such as multiple myeloma. Molecular Templates, Inc. shares closed up 52.44% on a little over 7 million shares traded yesterday. The clinical-stage oncology company was exploding on the news that it had announced an agreement with Japan's Takeda Pharmaceutical Co Ltd for jointly developing CD38-targeted ETNs for treating patients with diseases such as multiple myeloma.
- InvestorPlace•28 days ago
Why Altimmune Stock Is Skyrocketing Today
About two weeks ago, the Gaithersburg, Maryland-based company said that its intranasal egg-free flu vaccine medication NasoVax yielded positive data from its Phase 2a study. Altimmune’s vaccine candidate also proved to elicit a considerable T cell immune response when compared to Fluzone, which is a licensed injected influenza vaccine. Altimmune also has an anthrax vaccine, as well as a cancer immunotherapeutic product in Oncosyn that it is developing at the moment.
- GlobeNewswire•last month
Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine
Continued clean safety profile. An influenza specific mucosal antibody (IgA) response was demonstrated at all dose levels of NasoVAX, with the highest responses in the highest dose groups, while Fluzone and placebo groups demonstrated no response. Mucosal antibodies can be found in tears, saliva and nasal mucous and are a first line of immune defense thereby preventing influenza infection at the site of entry in the respiratory tract.
- GlobeNewswire•2 months ago
Altimmune Announces Initial Single-Dose Data from Its NasoShield Phase 1 Study
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced initial data from its Phase 1 study of NasoShield under investigation as a potential vaccine against anthrax. The purpose of the Phase 1 study was to assess the safety and immunogenicity of a single intranasal dose of NasoShield at four dose cohort levels. An additional cohort received a repeated dose of NasoShield at Day 21.
- ACCESSWIRE•2 months ago
Altimmune, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 15, 2018 / Altimmune, Inc. (NASDAQ: ALT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 15, 2018 at 8:30 AM Eastern Time. To ...
- GlobeNewswire•2 months ago
Altimmune Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Conference call and webcast scheduled for tomorrow, August 15, 2018, at 8:30am ET. GAITHERSBURG, Md., Aug. 14, 2018-- Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced financial ...
- GlobeNewswire•2 months ago
Altimmune to Announce Second Quarter 2018 Financial Results on August 15
GAITHERSBURG, Md., Aug. 07, 2018-- Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the quarter and year ended June 30, 2018 before ...
- ACCESSWIRE•4 months ago
Stock Performance Review on Alder Biopharma and Three Other Biotech Stocks
LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want a free Stock Review on ALDR sign up now at www.wallstequities.com/registration. Gains were broad based as seven out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and Altimmune Inc. (NASDAQ: ALT).
- Reuters•4 months ago
U.S. hedge fund Hudson Bay to open London office - sources
U.S. hedge fund Hudson Bay Capital is opening an office in Britain to expand its European trading book, two sources told Reuters on Tuesday. Hudson Bay, which runs $2.8 billion in assets across equity, credit and other assets, has hired a team of three for its new London base and plans to add more staff, the sources with direct knowledge of the matter said. Other U.S. hedge funds are have also increased investment in Europe, including high-profile activists such as Elliott Advisers, amid increased competition and less attractive valuations at home.
- Reuters•4 months ago
U.S. hedge fund Hudson Bay to open London office -sources
U.S. hedge fund Hudson Bay Capital is opening an office in Britain to expand its European trading book, two sources told Reuters on Tuesday. Hudson Bay, which runs $2.8 billion in assets across equity, credit and other assets, has hired a team of three for its new London base and plans to add more staff, the sources with direct knowledge of the matter said. Other U.S. hedge funds are have also increased investment in Europe, including high-profile activists such as Elliott Advisers, amid increased competition and less attractive valuations at home.
- Simply Wall St.•5 months ago
Does Altimmune Inc’s (NASDAQ:ALT) CEO Salary Reflect Performance?
Leading Altimmune Inc (NASDAQ:ALT) as the CEO, Bill Enright took the company to a valuation of US$9.21M. Understanding how CEOs are incentivised to run and grow their company is anRead More...
- Simply Wall St.•5 months ago
Who Are The Major Shareholders Of Altimmune Inc (NASDAQ:ALT)?
In this article, I’m going to take a look at Altimmune Inc’s (NASDAQ:ALT) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...
